ArticleFuture science OA2025
Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the safety and efficacy of TACE combined with durvalumab for treating advanced and metastatic BTC. Research design and methods: Data were collected retrospectively from a single center. The TACE procedures were performed 1 to 19 times, with repetitions occurring every 4 to 12 weeks based on the patient's liver function and tumor shrinkage. Durvalumab was given as an intravenous injection every three weeks at a dose of 1000 to 1500 mg.
resultsThe estimated median progression-free survival (PFS) was 9.0 months (95% CI: 6.8 to 11.2), with a 1-year PFS rate of 23.8%. The estimated median overall survival (OS) was 16.0 months (95% CI: 7.5 to 24.5), with a 1-year OS rate of 58.7%. The investigator-confirmed objective response rate (ORR) was 35.9%. Elevated baseline carcinoembryonic antigen (CEA) levels and neutrophil-to-lymphocyte ratio (NLR) ≥ 3 showed negative correlations with PFS (p = 0.035, CEA; p = 0.038, NLR) and OS (p = 0.040, NLR). Adverse events occurred in 36 patients (92.3%). Additionally, 7 patients (17.9%) experienced immune-mediated AEs (imAEs).
conclusionsThese results indicate promising efficacy and acceptable safety for the combination of TACE and durvalumab as a first-line treatment for advanced and metastatic BTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.